Form 4: Beta Bionics CCO Sells Shares for Tax Obligations

Beta Bionics' Chief Commercial Officer, Mark Hopman, sold 848 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported a transaction on September 2, 2025.
• He disposed of 848 shares of Common Stock.
• The shares were sold at a weighted average price of $18.8632 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Hopman beneficially owns 33,284 shares of Common Stock directly.
• The sale price range for the transaction was between $18.58 and $19.09.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares to cover tax obligations upon the vesting of restricted stock units, which is a common practice for executives and does not indicate a change in company fundamentals or management's outlook.

Positives

• The sale was for tax withholding obligations, indicating a routine event rather than a discretionary sale based on negative sentiment.
• The officer still retains a significant number of shares (33,284), maintaining alignment with shareholder interests.

Negatives

• A reduction in insider ownership, albeit for a specific tax purpose.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minimal impact as it is a small, routine sale for tax purposes, not indicative of a loss of confidence.
• Management: Mark Hopman's direct beneficial ownership is slightly reduced but remains substantial, maintaining alignment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Commercial Officer to cover tax withholding obligations associated with restricted stock unit vesting. Such transactions are common and typically do not reflect a change in the company's fundamental performance or the insider's long-term view of the company. Therefore, it does not provide a basis for altering an existing investment recommendation.

Keywords

Beta Bionics, BBNX, Mark Hopman, Chief Commercial Officer, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation